Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma

被引：0
|
作者：
Veenstra, David L. [1 ]
Guzauskas, Gregory F. [1 ]
Spencer, Scott J. [1 ]
Felizzi, Federico [2 ]
Launonen, Aino [2 ]
Dawson, Keith [3 ]
Masaquel, Anthony [3 ]
机构：
[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Genentech Inc, San Francisco, CA 94080 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
biosimilars; cost-effectiveness; immunochemotherapy; IBCL; indolent B-cell lymphoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-199
引用
收藏
页码：S280 / S280
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma
    Gong, Jinhong
    Shang, Jingjing
    Su, Dan
    Qian, Xiaodan
    Liu, Guangjun
    Sun, Zhiqiang
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (06) : 709 - 717
  • [32] Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
    Huo, Gengwei
    Liu, Wenjie
    Kang, Shuo
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [33] An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK
    Ray, Joshua A.
    Carr, Emma
    Lewis, Gavin
    Marcus, Robert
    VALUE IN HEALTH, 2010, 13 (04) : 346 - 357
  • [34] Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    Li, Shan
    Yuan, Dan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [35] Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
    Liu, Lulu
    Wang, Lei
    Chen, Li
    Ding, Yiling
    Zhang, Qilin
    Shu, Yamin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [36] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Peng-Fei Zhang
    Xuan-Qiong Shi
    Qiu Li
    Cost Effectiveness and Resource Allocation, 21
  • [37] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Shi, Xuan-Qiong
    Li, Qiu
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [38] Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
    Feng, Mingyang
    Chen, Yue
    Yang, Yang
    Li, Qiu
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [39] Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective
    P.-F Zhang
    F. Wen
    J. Zhou
    J.-X. Huang
    K.-X. Zhou
    Q.-J. Wu
    X.-Y. Wang
    M.-X. Zhang
    W.-T. Liao
    Q. Li
    Clinical and Translational Oncology, 2020, 22 : 103 - 110
  • [40] Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective
    Zhang, P. -F
    Wen, F.
    Zhou, J.
    Huang, J. -X.
    Zhou, K. -X.
    Wu, Q. -J.
    Wang, X. -Y.
    Zhang, M. -X.
    Liao, W. -T.
    Li, Q.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (01): : 103 - 110
12345